Results of the Conversion to Everolimus in Renal Transplant Recipients With Posttransplantation Malignancies

Transplantation Proceedings

Volumn 42, Issue 1, 2010, Pages 277-279

  Chiurchiu, C ^a   Carreno C A ^a   Schiavelli, R ^a   Petrone, H ^a   Balaguer, C ^a   Trimarchi, H ^a   Pujol, G S ^a   Novoa, P ^a   Acosta, F ^a   Gonzalez C ^a   Arriola, M ^a   Massari, P U ^a  

^a HOSPITAL PRIVADO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CAUSE OF DEATH; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GYNECOLOGIC CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHATIC SYSTEM TUMOR; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; SEMINOMA; SKIN CANCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTILYMPHOCYTE SERUM; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PROSTATIC NEOPLASMS; PROTEINURIA; SIROLIMUS; TIME FACTORS; TRIGLYCERIDES;

EID: 76749097116     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.11.017     Document Type: Article

References (16)

1. Mazuecos A., Muñoz Terol J.M., García Alvárez T., et al. Increase in malignancies as cause of death in renal transplant patients. Transplant Proc 41 (2009) 2159
2. Kasiske B.L., Snyder J.J., Gilbertson D.T., et al. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905
3. Campistol J., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
4. Kauffman H., Cherikh W., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883
5. Koehl G., Schlitt H., and Geissler E. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplant Rev 19 (2005) 20
6. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
7. Boratynska M., Zmonarsky S., and Klinger M. Recurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 6 (2006) 2018
8. Fernández A., Marcén R., Pascual J., et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 38 (2006) 2453
9. Boratynska M., Watorek E., Smolska D., et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 39 (2007) 2736
10. González E., Andrés A., Polanco N., et al. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. Transplant Proc 41 (2009) 2332
11. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27 (2009) 2630
12. Gomez-Camarero J., Salcedo M., Rincon D., et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 84 (2007) 786
13. Morgan T., Pitts E., Gross T., et al. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. The Prostate 68 (2008) 861
14. Bullock K., Hurwitz H., Uronis H., et al. Bevacizumab plus everolimus in refractory metastatic colorectal cancer. J Clin Oncol 27 suppl; abstr 4080 (2009) 15s
15. Lane H., Wood J., McSheehy P., et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15 (2009) 1612
16. Motzer R., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449